JP5675799B2 - 遅効性インスリン製剤 - Google Patents

遅効性インスリン製剤 Download PDF

Info

Publication number
JP5675799B2
JP5675799B2 JP2012518920A JP2012518920A JP5675799B2 JP 5675799 B2 JP5675799 B2 JP 5675799B2 JP 2012518920 A JP2012518920 A JP 2012518920A JP 2012518920 A JP2012518920 A JP 2012518920A JP 5675799 B2 JP5675799 B2 JP 5675799B2
Authority
JP
Japan
Prior art keywords
arg
asp
pro
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012518920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532179A (ja
JP2012532179A5 (https=
Inventor
イザベル・シェットレ
クリスツィアーネ・フュルスト
フェレナ・ジーフケ−ヘンツラー
ゲリット・ハオック
ヴァルター・カム
ユリア・シュニーデルス
ユッタ・ツァールス
ゲルト・ヴォルフ
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2012532179A publication Critical patent/JP2012532179A/ja
Publication of JP2012532179A5 publication Critical patent/JP2012532179A5/ja
Application granted granted Critical
Publication of JP5675799B2 publication Critical patent/JP5675799B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2012518920A 2009-07-06 2010-07-02 遅効性インスリン製剤 Expired - Fee Related JP5675799B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE102009031750 2009-07-06
DE102009031750.3 2009-07-06
US26435309P 2009-11-25 2009-11-25
US61/264,353 2009-11-25
DE102010013133.4 2010-03-27
DE102010013133 2010-03-27
PCT/EP2010/059438 WO2011003823A1 (de) 2009-07-06 2010-07-02 Langsamwirkende insulinzubereitungen

Publications (3)

Publication Number Publication Date
JP2012532179A JP2012532179A (ja) 2012-12-13
JP2012532179A5 JP2012532179A5 (https=) 2013-08-08
JP5675799B2 true JP5675799B2 (ja) 2015-02-25

Family

ID=43428815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012518920A Expired - Fee Related JP5675799B2 (ja) 2009-07-06 2010-07-02 遅効性インスリン製剤

Country Status (7)

Country Link
US (1) US20120232002A1 (https=)
EP (1) EP2451471A1 (https=)
JP (1) JP5675799B2 (https=)
AR (1) AR077455A1 (https=)
TW (1) TW201113032A (https=)
UY (1) UY32765A (https=)
WO (1) WO2011003823A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102596175A (zh) * 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) * 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
MX2016008979A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
BR112016015851A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) * 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
JP2001521006A (ja) * 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2002067969A2 (en) * 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
RU2524150C2 (ru) * 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
MY152979A (en) * 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
US20120241356A1 (en) * 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
CN102596175A (zh) * 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
MY180661A (en) * 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine

Also Published As

Publication number Publication date
US20120232002A1 (en) 2012-09-13
JP2012532179A (ja) 2012-12-13
EP2451471A1 (de) 2012-05-16
UY32765A (es) 2011-01-31
WO2011003823A1 (de) 2011-01-13
AR077455A1 (es) 2011-08-31
TW201113032A (en) 2011-04-16

Similar Documents

Publication Publication Date Title
JP5675799B2 (ja) 遅効性インスリン製剤
US20250255803A1 (en) Insulin preparations containing methionine
US20240108692A1 (en) Combination of an insulin and a glp-1-agonist
US20120241356A1 (en) Heat- and vibration-stable insulin preparations
RU2537239C2 (ru) Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
JP2004523589A (ja) 改善された安定性を有するいかなる量の亜鉛も含有しないかまたはほんの少量の亜鉛しか含有しないインスリン製剤
JP2005537232A (ja) アミリンアゴニストペプチドの製剤
HK1166266A (en) Aqueous preparations comprising methionine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141224

R150 Certificate of patent or registration of utility model

Ref document number: 5675799

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees